ArticleJournal of neuro-oncology2025
Synergistic antitumor and radiosensitizing effects of α-sulfoquinovosyl-acylpropanediol (SQAP) via PI3K/Akt inhibition and DNA repair impairment in glioblastoma.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRadiotherapy remains a key treatment modality for glioblastoma (GBM), but therapeutic resistance and radiation-induced toxicity severely limit its efficacy. Therefore, the development of novel, safe, and effective radiosensitizers is urgently needed. α-Sulfoquinovosylacylpropandiol (SQAP), a marine-derived compound, has demonstrated potent radiosensitizing effects in cancer cells by improving tumor oxygenation and interfering with DNA repair. However, its impact on GBM has not yet been investigated. This study aimed to evaluate the biological effects of SQAP on GBM cells and assess its potential as a radiosensitizer for future clinical application.
methodsIn vitro analyses-including cell viability, colony formation, immunoblotting, quantitative reverse transcription polymerase chain reaction, immunocytochemistry, and cell death/proliferation assays-were conducted to examine SQAP's mechanisms of action. In vivo efficacy and safety were evaluated using a murine intracranial glioma model.
resultsSQAP inhibited GBM cell proliferation while sparing normal astrocytes. In combination with radiotherapy, SQAP significantly reduced colony formation and enhanced cell death without affecting mitosis. SQAP decreased PI3K/Akt phosphorylation and modulated the expression of downstream apoptotic and cell cycle-related proteins. Additionally, SQAP suppressed HIF-1α and VEGF expression. Although SQAP alone did not cause DNA damage, it delayed radiotherapy-induced DNA repair, as shown by prolonged γH2AX expression and reduced 53BP1 nuclear expression.
conclusionSQAP exerts both antitumor and radiosensitizing effects in GBM models by inhibiting PI3K/Akt signaling, suppressing hypoxia-related pathways, and impairing DNA repair. These findings support its potential as a promising adjunctive agent in GBM therapy.
Indexed as
Identifiers
40788564What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.